India, Aug. 12 -- Eli Lilly (LLY) on Wednesday filed six lawsuits against U.S. companies it accused of illegally selling unauthorized versions of its experimental obesity drug retatrutide, escalating its efforts to crack down on black-market products before the medicine receives regulatory approval.
The lawsuits target a range of businesses, including compounding pharmacies, medical spas and online sellers that allegedly marketed products claiming to contain retatrutide. The companies named in the lawsuits are Aesthetic Envy Cosmetic Centers, Astra LLC, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide Co.
Retatrutide remains in Phase 3 clinical trials for obesity, type 2 diabetes and related conditions and has no...